On May 29, 2019, Ivan Persiyanov delivered notice of his resignation from the board of directors (the “Board”) of Cleveland BioLabs, Inc. (the “Company”). His resignation will be effective on June 1, 2019. Mr. Persiyanov did not resign because of a disagreement with the Company or the other members of the Board on any matter relating to the Company’s operations, policies, or practices. Ms. Persiyanov was most recently reelected director by the Company’s stockholders after being nominated by the Board as a designee of David Davidovich, the Company’s majority stockholder, under the terms of the previously disclosed securities purchase agreement between Mr. Davidovich and the Company, dated as of June 24, 2015.

About Cleveland BioLabs, Inc. (NASDAQ:CBLI)

Cleveland BioLabs, Inc. (CBLI) is a biopharmaceutical company. The Company’s programs are focused developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is entolimod, an immuno-stimulatory agent, which the Company is developing as a radiation countermeasure and an immunotherapy for oncology and other indications. It also has an additional clinical-stage program and multiple projects in different stages of preclinical drug development. Its products include Entolimod, CBLB612, CBL0137 and Mobilan. Entolimod is a toll-like receptor 5 (TLR5). CBLB612 is a compound-based upon a natural activator of another tissue-specific component of the immune system. Mobilan is a recombinant non-replicating adenovirus that directs expression of TLR5.